These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25129565)

  • 21. Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria.
    Starzengruber P; Segagni Lusignani L; Wrba T; Mitteregger D; Indra A; Graninger W; Presterl E; Diab-Elschahawi M
    Wien Klin Wochenschr; 2014 Jul; 126(13-14):427-30. PubMed ID: 24903143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors predictive of severe Clostridium difficile infection depend on the definition used.
    Khanafer N; Barbut F; Eckert C; Perraud M; Demont C; Luxemburger C; Vanhems P
    Anaerobe; 2016 Feb; 37():43-8. PubMed ID: 26335160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.
    He T; Kaplan SE; Gomez LA; Lu X; Ramanathan LV; Kamboj M; Tang YW
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2341-2346. PubMed ID: 30242543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clostridioides difficile toxin B gen amplification cycle threshold as a predictor of severity].
    Sante L; Kohan R; Blanco-Hortas A; Díaz Z; Lecuona M
    Rev Chilena Infectol; 2022 Feb; 39(1):29-34. PubMed ID: 35735277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of clinical severity score indices for Clostridium difficile infection.
    Fujitani S; George WL; Murthy AR
    Infect Control Hosp Epidemiol; 2011 Mar; 32(3):220-8. PubMed ID: 21460506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of Clostridioides difficile infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period.
    Aljafel NA; Al-Shaikhy HH; Alnahdi MA; Thabit AK
    J Infect Public Health; 2020 Aug; 13(8):1156-1160. PubMed ID: 32276872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
    McDonald LC; Gerding DN; Johnson S; Bakken JS; Carroll KC; Coffin SE; Dubberke ER; Garey KW; Gould CV; Kelly C; Loo V; Shaklee Sammons J; Sandora TJ; Wilcox MH
    Clin Infect Dis; 2018 Mar; 66(7):e1-e48. PubMed ID: 29462280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
    Miller R; Morillas JA; Brizendine KD; Fraser TG
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal host biomarkers predicting severity of Clostridioides difficile infection.
    Golizeh M; Winter K; Roussel L; Landekic M; Langelier M; Loo VG; Ndao M; Vinh DC
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of Clostridioides (Clostridium) difficile infection in adults: a summary of recommendations from the 2017 IDSA/SHEA clinical practice guideline.
    Ma J; Dubberke E
    Pol Arch Intern Med; 2019 Mar; 129(3):189-198. PubMed ID: 30457126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic stewardship and the 2017 update of the IDSA-SHEA Clinical Practice Guidelines for Clostridium difficile Infection.
    Madden GR; Poulter MD; Sifri CD
    Diagnosis (Berl); 2018 Sep; 5(3):119-125. PubMed ID: 29990306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Usefulness of the "MN Criteria" - the Clostridioides difficile Infection Severity Scoring System - in the Japanese Setting.
    Asaoka M; Horita Y; Wachino C; Kondo S; Hotta Y; Kataoka T; Sanagawa A; Hayakawa T; Nakamura A; Kimura K
    Intern Med; 2023 Jan; 62(1):59-67. PubMed ID: 35650131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy.
    Miller MA; Louie T; Mullane K; Weiss K; Lentnek A; Golan Y; Kean Y; Sears P
    BMC Infect Dis; 2013 Mar; 13():148. PubMed ID: 23530807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
    Robin C; Héquette-Ruz R; Guery B; Boyle E; Herbaux C; Galperine T
    Med Mal Infect; 2017 Dec; 47(8):532-539. PubMed ID: 28823390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections.
    Jacobson SM; Slain D
    Am J Health Syst Pharm; 2015 Nov; 72(21):1871-5. PubMed ID: 26490821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.
    Dubberke ER; Han Z; Bobo L; Hink T; Lawrence B; Copper S; Hoppe-Bauer J; Burnham CA; Dunne WM
    J Clin Microbiol; 2011 Aug; 49(8):2887-93. PubMed ID: 21697328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of 30-day all-cause mortality in metronidazole-treated patients with Clostridium difficile infection.
    Venugopal AA; Szpunar S; Sanchez K; Sessions R; Johnson LB
    Scand J Infect Dis; 2013 Oct; 45(10):786-90. PubMed ID: 23746336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of guidelines for the diagnosis and treatment of Clostridioides difficile infection.
    Gu T; Li W; Yang LL; Yang SM; He Q; He HY; Sun DL
    Front Cell Infect Microbiol; 2022; 12():926482. PubMed ID: 36111240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.